QQQ   390.50 (+1.42%)
AAPL   194.32 (+1.04%)
MSFT   370.69 (+0.51%)
META   326.64 (+2.89%)
GOOGL   136.97 (+5.35%)
AMZN   146.74 (+1.54%)
TSLA   240.84 (+0.61%)
NVDA   464.24 (+2.02%)
NIO   7.47 (-3.61%)
BABA   72.32 (+1.16%)
AMD   128.13 (+9.68%)
T   17.08 (+0.83%)
F   10.85 (+1.50%)
MU   73.79 (+0.90%)
CGC   0.72 (+2.77%)
GE   119.44 (-0.31%)
DIS   92.50 (+1.09%)
AMC   6.85 (+0.88%)
PFE   28.73 (-0.21%)
PYPL   58.54 (-1.66%)
XOM   98.20 (-0.92%)
QQQ   390.50 (+1.42%)
AAPL   194.32 (+1.04%)
MSFT   370.69 (+0.51%)
META   326.64 (+2.89%)
GOOGL   136.97 (+5.35%)
AMZN   146.74 (+1.54%)
TSLA   240.84 (+0.61%)
NVDA   464.24 (+2.02%)
NIO   7.47 (-3.61%)
BABA   72.32 (+1.16%)
AMD   128.13 (+9.68%)
T   17.08 (+0.83%)
F   10.85 (+1.50%)
MU   73.79 (+0.90%)
CGC   0.72 (+2.77%)
GE   119.44 (-0.31%)
DIS   92.50 (+1.09%)
AMC   6.85 (+0.88%)
PFE   28.73 (-0.21%)
PYPL   58.54 (-1.66%)
XOM   98.20 (-0.92%)
QQQ   390.50 (+1.42%)
AAPL   194.32 (+1.04%)
MSFT   370.69 (+0.51%)
META   326.64 (+2.89%)
GOOGL   136.97 (+5.35%)
AMZN   146.74 (+1.54%)
TSLA   240.84 (+0.61%)
NVDA   464.24 (+2.02%)
NIO   7.47 (-3.61%)
BABA   72.32 (+1.16%)
AMD   128.13 (+9.68%)
T   17.08 (+0.83%)
F   10.85 (+1.50%)
MU   73.79 (+0.90%)
CGC   0.72 (+2.77%)
GE   119.44 (-0.31%)
DIS   92.50 (+1.09%)
AMC   6.85 (+0.88%)
PFE   28.73 (-0.21%)
PYPL   58.54 (-1.66%)
XOM   98.20 (-0.92%)
QQQ   390.50 (+1.42%)
AAPL   194.32 (+1.04%)
MSFT   370.69 (+0.51%)
META   326.64 (+2.89%)
GOOGL   136.97 (+5.35%)
AMZN   146.74 (+1.54%)
TSLA   240.84 (+0.61%)
NVDA   464.24 (+2.02%)
NIO   7.47 (-3.61%)
BABA   72.32 (+1.16%)
AMD   128.13 (+9.68%)
T   17.08 (+0.83%)
F   10.85 (+1.50%)
MU   73.79 (+0.90%)
CGC   0.72 (+2.77%)
GE   119.44 (-0.31%)
DIS   92.50 (+1.09%)
AMC   6.85 (+0.88%)
PFE   28.73 (-0.21%)
PYPL   58.54 (-1.66%)
XOM   98.20 (-0.92%)

Revolution Medicines Stock Price, News & Analysis (NASDAQ:RVMD)

$24.70
+0.73 (+3.05%)
(As of 02:51 PM ET)
Compare
Today's Range
$23.82
$24.82
50-Day Range
$18.35
$34.12
52-Week Range
$15.44
$35.60
Volume
776,799 shs
Average Volume
1.47 million shs
Market Capitalization
$2.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.50

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
45.2% Upside
$35.50 Price Target
Short Interest
Bearish
14.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.00mentions of Revolution Medicines in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.81 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.48) to ($3.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

372nd out of 958 stocks

Biotechnology Industry

24th out of 75 stocks


RVMD stock logo

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

RVMD Stock News Headlines

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Cancer Player Revolution Medicines Gets Bullish Rating: Here's Details
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
What 6 Analyst Ratings Have To Say About Revolution Medicines
Stifel Nicolaus Keeps Their Buy Rating on Revolution Medicines (RVMD)
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
338
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.50
High Stock Price Target
$47.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+48.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-248,710,000.00
Net Margins
-1,003.36%
Pretax Margin
-1,281.44%

Debt

Sales & Book Value

Annual Sales
$35.38 million
Book Value
$7.72 per share

Miscellaneous

Free Float
100,252,000
Market Cap
$2.63 billion
Optionable
Not Optionable
Beta
1.50
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives















RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price target for 2024?

8 Wall Street research analysts have issued twelve-month target prices for Revolution Medicines' shares. Their RVMD share price targets range from $23.00 to $47.00. On average, they expect the company's share price to reach $35.50 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2023?

Revolution Medicines' stock was trading at $23.82 at the beginning of 2023. Since then, RVMD stock has increased by 2.6% and is now trading at $24.45.
View the best growth stocks for 2023 here
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) issued its earnings results on Monday, November, 6th. The company reported ($0.99) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.02. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 38.92%. During the same period in the prior year, the company earned ($0.87) EPS.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.65%), Column Group LLC (1.12%), Ameriprise Financial Inc. (1.11%), Northern Trust Corp (0.85%), Morgan Stanley (0.73%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -